Get the Daily Brief
Latest Biotech News
Cytokinetics wins FDA nod – Myqorzo to compete with Bristol Myers
The FDA granted approval to Cytokinetics’ heart drug Myqorzo, marking the first regulatory clearance in the company’s history and introducing a direct competitor to Bristol Myers Squibb’s Camzyos....
Antivirals cut post‑COVID cardiac risk – target trial emulation shows benefit
A Nature Communications target‑trial emulation led by Guo, Wei, Lin and colleagues showed that antiviral treatments nirmatrelvir/ritonavir and molnupiravir reduced the risk of cardiovascular...
Antisense oligo reverses SMA defects in organoids — translational step
Researchers reported in Nature Communications that a targeted antisense oligonucleotide (ASO) therapy reversed developmental defects in spinal muscular atrophy (SMA) organoid models. The study...
Fruquintinib plus sintilimab shows activity in pMMR endometrial cancer
A multicenter Phase Ib/II single‑arm trial reported activity for the combination of fruquintinib and sintilimab in advanced mismatch‑repair proficient (pMMR) endometrial cancer. Investigators...
Multivalency and FcγRIIB engagement amplify anti‑CD27 immunotherapy
A Nature Communications study demonstrated that engineering anti‑CD27 agonists for multivalency and engagement of the inhibitory FcγRIIB receptor substantially enhances antitumor activity. The...
Graph‑attention AI predicts drug synergy: KGLGANSynergy unveiled
Researchers published KGLGANSynergy, a knowledge‑graph and attention‑based framework that improves prediction of drug synergy across compound pairs. The model integrates local and global attention...
New LRRK2 variant P1446L drives neurodegeneration via microglial inflammation
Investigators identified a novel LRRK2 mutation (P1446L) that promotes dopaminergic neuron loss through microglia‑driven inflammation and apoptosis, according to a paper in npj Parkinson’s...
MINFLUX maps cardiac ryanodine receptor in 3D in living cells
Researchers applied MINFLUX super‑resolution microscopy to resolve the subunit architecture and three‑dimensional orientation of cardiac ryanodine receptors (RyR) inside living cells. The study...
Autophagy sorts mitochondria to define CD8+ T cell fate and division
Teams at the Max Delbrück Center and University of Oxford reported in Nature Cell Biology that autophagy regulates mitochondrial inheritance during asymmetric CD8+ T cell division, directing...
Antibiotic exposure associated with altered breast cancer survival in population study
A large population‑based cohort study from England and Wales, published in Nature Communications, found associations between antibiotic use and breast cancer survival outcomes. The analysis...
Cytokinetics lands first FDA approval – Myqorzo cleared for obstructive HCM
The FDA approved Cytokinetics’ Myqorzo, giving the company its first U.S. drug authorization after a 27-year run. Regulators cleared the therapy to treat obstructive hypertrophic cardiomyopathy...
BioMarin to buy Amicus for $4.8B – Fabry and Pompe assets added
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, adding marketed treatments for Fabry and Pompe diseases to its rare-disease portfolio. The transaction accelerates BioMarin’s...
Insmed stock tumbles after Brinsupri clinical setback
Insmed reported a clinical setback for Brinsupri that triggered an immediate market-cap reduction, according to BioCentury’s clinical report. The failure or delay in Brinsupri’s development...
Nonprofit brings abandoned rare-disease gene therapy to market – scalability questioned
A nonprofit organization succeeded in taking an abandoned rare-disease gene therapy to market, reporting a path to patient access where commercial sponsors had exited. The group partnered with...
U.S. research funding frozen – NIH grant reviews and operations curtailed
The U.S. government enacted operational freezes across the NIH in 2025, halting grant reviews, external communications, travel, and hiring—moves that cost the research community more than $1.5...
U.S. vaccine schedule overhaul proposed — experts warn of risks
Reporting indicates U.S. officials are considering aligning the childhood vaccine schedule more closely with Denmark by removing or reducing routine immunizations for diseases such as rotavirus,...
JAX completes NYSCF acquisition: unified nonprofit aims to accelerate translational genetics
The Jackson Laboratory finalized its acquisition of the New York Stem Cell Foundation, launching a unified nonprofit that combines JAX’s mouse genetics with NYSCF’s automated human stem-cell...
Antisense oligonucleotides reverse SMA defects in organoid models – Nature Commun.
A Nature Communications study showed targeted antisense oligonucleotide (ASO) therapy could rescue developmental defects in spinal muscular atrophy (SMA) organoids. The team demonstrated...
Fruquintinib plus sintilimab shows activity in pMMR advanced endometrial cancer
A multicenter Phase Ib/II trial reported clinically meaningful responses combining fruquintinib, a VEGFR inhibitor, with sintilimab, an anti‑PD‑1 antibody, in patients with...
Oral antivirals tied to lower post‑COVID cardiovascular risk – target trial emulation
A Nature Communications target trial emulation found that nirmatrelvir/ritonavir (Paxlovid) and molnupiravir reduced the risk of cardiovascular events after COVID‑19 infection. The study used...